NCT00080041已完成1 期
Phase I Trial of Motexafin Gadolinium (MGd) and Docetaxel Administered at 3-Week Intervals for Advanced Solid Tumors
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Determine the Dose Limiting Toxicity at 3 weeks (1 cycle), and the Maximum Tolerated Dose at 24 weeks (6 cycles).
研究概览
简要总结
The primary purpose of this study is to evaluate the safety, toxicities, and dosage for investigational drug Motexafin Gadolinium administered with docetaxel to patients with advanced solid tumors. Secondly, tumor response to the combined treatment will be evaluated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •≥ 18 years old
- •Histologically or cytologically confirmed diagnosis of cancer (i.e., Unresectable locally advanced or metastatic non-small-cell lung carcinoma (NSCLC) that had progressed during or after one or more chemotherapy regimens; Metastatic breast cancer; Hormone-refractory prostate cancer; Recurrent or refractory ovarian cancer; Sarcoma)
- •ECOG performance status score either 0 or 1
- •Willing and able to provide written informed consent
排除标准
- •Laboratory Values of:
- •Absolute neutrophil count < 2000/µL
- •Platelet count < 100,00/µL
- •AST or ALT > 1.5 x the upper limit of normal
- •Alkaline phosphatase > 5 x the upper limit of normal
- •Bilirubin > ULN
- •Creatinine > 2.0 mg/dL
- •Peripheral neuropathy NCI CTC Grade 3 or higher
- •Chemotherapy, radiation therapy, immunotherapy, or systemic biologic
- •anticancer therapy within 21 days before beginning study treatment
- •Known history of brain metastases or spinal cord compression
- •Uncontrolled hypertension
- •Myocardial infarction within 6 months before beginning study treatment
- •Unstable angina pectoris, uncontrolled congestive heart failure, or uncontrolled serious arrhythmias
- •Known sensitivity to or intolerable adverse effects from taxanes or polysorbate 80
- •Known history of porphyria (testing not required at screening)
- •Known history of glucose-6-phosphate dehydrogenase (G6PD) deficiency (testing not required at screening)
- •Known history of HIV infection (testing not required at screening)
- •Female who is pregnant or lactating (pregnancy test is required for all female patients of childbearing potential)
- •Female of childbearing potential or sexually active male unwilling to use adequate contraceptive protection
- •Physical or mental condition that makes patient unable to complete specified follow-up assessments
结局指标
主要结局
Determine the Dose Limiting Toxicity at 3 weeks (1 cycle), and the Maximum Tolerated Dose at 24 weeks (6 cycles).
次要结局
- Frequency of tumor responses at weeks 6, 12 and 18.
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study of Motexafin Gadolinium and Docetaxel for Advanced CancerBreast NeoplasmsOvarian NeoplasmsLung NeoplasmsGastrointestinal NeoplasmsProstatic NeoplasmsNCT00120939Pharmacyclics LLC.25
已完成
1 期
Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaSmall Lymphocytic LymphomaLymphomaLeukemiaChronic Lymphocytic LeukemiaNCT00290004Pharmacyclics LLC.35
已完成
1 期
A Study of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC)Non-Small-Cell Lung CarcinomaCarcinoma, BronchogenicNCT00102505Pharmacyclics LLC.36
已完成
1 期
A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant GliomasOligodendrogliomaBrain NeoplasmGlioblastomaGliomaAstrocytomaNCT00080054Pharmacyclics LLC.24
终止
1 期
Motexafin Gadolinium With Chemotherapy and Radiation Therapy for the Treatment of Advanced Head and Neck CancerHead and Neck CancerOropharynx CancerLarynx CancerHypopharynx CancerNCT00080028Pharmacyclics LLC.18